Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma

Peter Bailey, David K. Chang, Marie Andreé Forget, Francis A San Lucas, Hector A. Alvarez, Cara Haymaker, Chandrani Chattopadhyay, Sun Hee Kim, Suhendan Ekmekcioglu, Elizabeth A. Grimm, Andrew V. Biankin, Patrick Hwu, Anirban Maitra, Jason Roszik

Research output: Contribution to journalArticle

Abstract

Immunotherapy approaches for pancreatic ductal adenocarcinoma (PDAC) have met with limited success. It has been postulated that a low mutation load may lead to a paucity of T cells within the tumor microenvironment (TME). However, it is also possible that while neoantigens are present, an effective immune response cannot be generated due to an immune suppressive TME. To discern whether targetable neoantigens exist in PDAC, we performed a comprehensive study using genomic profiles of 221 PDAC cases extracted from public databases. Our findings reveal that: (a) nearly all PDAC samples harbor potentially targetable neoantigens; (b) T cells are present but generally show a reduced activation signature; and (c) markers of efficient antigen presentation are associated with a reduced signature of markers characterizing cytotoxic T cells. These findings suggest that despite the presence of tumor specific neoepitopes, T cell activation is actively suppressed in PDAC. Further, we identify iNOS as a potential mediator of immune suppression that might be actionable using pharmacological avenues.

Original languageEnglish (US)
Article number35848
JournalScientific Reports
Volume6
DOIs
StatePublished - Oct 20 2016
Externally publishedYes

Fingerprint

Immunotherapy
Adenocarcinoma
T-Lymphocytes
Tumor Microenvironment
Differentiation Antigens
Antigen Presentation
Databases
Pharmacology
Mutation
Neoplasms

ASJC Scopus subject areas

  • General

Cite this

Bailey, P., Chang, D. K., Forget, M. A., Lucas, F. A. S., Alvarez, H. A., Haymaker, C., ... Roszik, J. (2016). Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Scientific Reports, 6, [35848]. https://doi.org/10.1038/srep35848

Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. / Bailey, Peter; Chang, David K.; Forget, Marie Andreé; Lucas, Francis A San; Alvarez, Hector A.; Haymaker, Cara; Chattopadhyay, Chandrani; Kim, Sun Hee; Ekmekcioglu, Suhendan; Grimm, Elizabeth A.; Biankin, Andrew V.; Hwu, Patrick; Maitra, Anirban; Roszik, Jason.

In: Scientific Reports, Vol. 6, 35848, 20.10.2016.

Research output: Contribution to journalArticle

Bailey, P, Chang, DK, Forget, MA, Lucas, FAS, Alvarez, HA, Haymaker, C, Chattopadhyay, C, Kim, SH, Ekmekcioglu, S, Grimm, EA, Biankin, AV, Hwu, P, Maitra, A & Roszik, J 2016, 'Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma', Scientific Reports, vol. 6, 35848. https://doi.org/10.1038/srep35848
Bailey P, Chang DK, Forget MA, Lucas FAS, Alvarez HA, Haymaker C et al. Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Scientific Reports. 2016 Oct 20;6. 35848. https://doi.org/10.1038/srep35848
Bailey, Peter ; Chang, David K. ; Forget, Marie Andreé ; Lucas, Francis A San ; Alvarez, Hector A. ; Haymaker, Cara ; Chattopadhyay, Chandrani ; Kim, Sun Hee ; Ekmekcioglu, Suhendan ; Grimm, Elizabeth A. ; Biankin, Andrew V. ; Hwu, Patrick ; Maitra, Anirban ; Roszik, Jason. / Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. In: Scientific Reports. 2016 ; Vol. 6.
@article{df818e211fd84d358a9369bc48023c11,
title = "Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma",
abstract = "Immunotherapy approaches for pancreatic ductal adenocarcinoma (PDAC) have met with limited success. It has been postulated that a low mutation load may lead to a paucity of T cells within the tumor microenvironment (TME). However, it is also possible that while neoantigens are present, an effective immune response cannot be generated due to an immune suppressive TME. To discern whether targetable neoantigens exist in PDAC, we performed a comprehensive study using genomic profiles of 221 PDAC cases extracted from public databases. Our findings reveal that: (a) nearly all PDAC samples harbor potentially targetable neoantigens; (b) T cells are present but generally show a reduced activation signature; and (c) markers of efficient antigen presentation are associated with a reduced signature of markers characterizing cytotoxic T cells. These findings suggest that despite the presence of tumor specific neoepitopes, T cell activation is actively suppressed in PDAC. Further, we identify iNOS as a potential mediator of immune suppression that might be actionable using pharmacological avenues.",
author = "Peter Bailey and Chang, {David K.} and Forget, {Marie Andre{\'e}} and Lucas, {Francis A San} and Alvarez, {Hector A.} and Cara Haymaker and Chandrani Chattopadhyay and Kim, {Sun Hee} and Suhendan Ekmekcioglu and Grimm, {Elizabeth A.} and Biankin, {Andrew V.} and Patrick Hwu and Anirban Maitra and Jason Roszik",
year = "2016",
month = "10",
day = "20",
doi = "10.1038/srep35848",
language = "English (US)",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma

AU - Bailey, Peter

AU - Chang, David K.

AU - Forget, Marie Andreé

AU - Lucas, Francis A San

AU - Alvarez, Hector A.

AU - Haymaker, Cara

AU - Chattopadhyay, Chandrani

AU - Kim, Sun Hee

AU - Ekmekcioglu, Suhendan

AU - Grimm, Elizabeth A.

AU - Biankin, Andrew V.

AU - Hwu, Patrick

AU - Maitra, Anirban

AU - Roszik, Jason

PY - 2016/10/20

Y1 - 2016/10/20

N2 - Immunotherapy approaches for pancreatic ductal adenocarcinoma (PDAC) have met with limited success. It has been postulated that a low mutation load may lead to a paucity of T cells within the tumor microenvironment (TME). However, it is also possible that while neoantigens are present, an effective immune response cannot be generated due to an immune suppressive TME. To discern whether targetable neoantigens exist in PDAC, we performed a comprehensive study using genomic profiles of 221 PDAC cases extracted from public databases. Our findings reveal that: (a) nearly all PDAC samples harbor potentially targetable neoantigens; (b) T cells are present but generally show a reduced activation signature; and (c) markers of efficient antigen presentation are associated with a reduced signature of markers characterizing cytotoxic T cells. These findings suggest that despite the presence of tumor specific neoepitopes, T cell activation is actively suppressed in PDAC. Further, we identify iNOS as a potential mediator of immune suppression that might be actionable using pharmacological avenues.

AB - Immunotherapy approaches for pancreatic ductal adenocarcinoma (PDAC) have met with limited success. It has been postulated that a low mutation load may lead to a paucity of T cells within the tumor microenvironment (TME). However, it is also possible that while neoantigens are present, an effective immune response cannot be generated due to an immune suppressive TME. To discern whether targetable neoantigens exist in PDAC, we performed a comprehensive study using genomic profiles of 221 PDAC cases extracted from public databases. Our findings reveal that: (a) nearly all PDAC samples harbor potentially targetable neoantigens; (b) T cells are present but generally show a reduced activation signature; and (c) markers of efficient antigen presentation are associated with a reduced signature of markers characterizing cytotoxic T cells. These findings suggest that despite the presence of tumor specific neoepitopes, T cell activation is actively suppressed in PDAC. Further, we identify iNOS as a potential mediator of immune suppression that might be actionable using pharmacological avenues.

UR - http://www.scopus.com/inward/record.url?scp=84992365723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992365723&partnerID=8YFLogxK

U2 - 10.1038/srep35848

DO - 10.1038/srep35848

M3 - Article

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 35848

ER -